An isotope dilution-liquid chromatography-tandem mass spectrometry (ID-LC-MS/MS)-based candidate reference measurement procedure for the quantification of levetiracetam in human serum and plasma
Author:
Kobel Anja1, Schierscher Tobias1, Singh Neeraj2, Salzmann Linda1, Liesch Franziska2, Bauland Friederike3, Geistanger Andrea2, Risch Lorenz1ORCID, Geletneky Christian2, Seger Christoph1, Taibon Judith2
Affiliation:
1. Dr. Risch Ostschweiz AG , Buchs , Switzerland 2. Roche Diagnostics GmbH , Penzberg , Germany 3. Chrestos Concept GmbH & Co. KG , Essen , Germany
Abstract
Abstract
Objectives
To develop an isotope dilution-liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based candidate reference measurement procedure (RMP) for levetiracetam quantification in human serum and plasma.
Methods
Quantitative nuclear magnetic resonance spectroscopy (qNMR) was used to characterize the RMP material to ensure traceability to SI units. To quantify levetiracetam, an LC-MS/MS method was optimized using a C8 column for chromatographic separation following protein-precipitation-based sample preparation. Spiked matrix samples of serum and plasma were used to test selectivity and specificity. Matrix effects were determined by performing a post-column infusion experiment and comparing standard line slopes. Precision and accuracy were evaluated over 5 days. Measurement uncertainty was evaluated according to the Guide to the Expression of Uncertainty in Measurement (GUM).
Results
The RMP was proven to be highly selective and specific with no evidence of a matrix effect, allowing for quantification of levetiracetam within the range of 1.53–90.0 μg/mL. Intermediate precision was <2.2% and repeatability was 1.1–1.7% across all concentrations. The relative mean bias ranged from −2.5% to −0.3% across all levels and matrices within the measuring range. Diluted samples were found with a mean bias ranging from −0.1 to 2.9%. The predefined acceptance criterion for measurement uncertainty was met and determined for individual measurements independently of the concentration level and sample type to be ≤4.0% (k=2).
Conclusions
We present a novel LC-MS/MS)-based candidate RMP for levetiracetam in human serum and plasma. Its expanded measurement uncertainty of ≤4.0% meets the clinical needs in levetiracetam monitoring. Utilizing qNMR to characterize levetiracetam reference materials allowed metrological traceability to SI units.
Publisher
Walter de Gruyter GmbH
Subject
Biochemistry (medical),Clinical Biochemistry,General Medicine
Reference35 articles.
1. Silva, R, Almeida, A, Bicker, J, Gonçalves, J, Carona, A, Silva, A, et al.. Pharmacokinetic monitoring of levetiracetam in Portuguese refractory epileptic patients: effect of gender, weight and concomitant therapy. Pharmaceutics 2020;12:943. https://doi.org/10.3390/pharmaceutics12100943. 2. Howard, P, Remi, J, Remi, C, Charlesworth, S, Whalley, H, Bhatia, R, et al.. Levetiracetam. J Pain Symptom Manag 2018;56:645–9. https://doi.org/10.1016/j.jpainsymman.2018.07.012. 3. Deshpande, LS, Delorenzo, RJ. Mechanisms of levetiracetam in the control of status epilepticus and epilepsy. Front Neurol 2014;5:11. https://doi.org/10.3389/fneur.2014.00011. 4. Lynch, BA, Lambeng, N, Nocka, K, Kensel-Hammes, P, Bajjalieh, SM, Matagne, A, et al.. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A 2004;101:9861–6. https://doi.org/10.1073/pnas.0308208101. 5. Hiemke, C, Bergemann, N, Clement, HW, Conca, A, Deckert, J, Domschke, K, et al.. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry 2018;51:9–62. https://doi.org/10.1055/s-0043-116492.
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|